While progress is being made, more than one in three adults in Oklahoma still lives with obesity, and many continue to struggle with weight-related conditions such as hypertension, diabetes and sleep apnea
Tirzepatide which targets both GLP-1 and GIP receptors has shown even more dramatic early results: weight loss of 1020 kg and insulin dose reductions exceeding 30% in observational and phase 2 data, with improved CGM time in range
Dysesthesia is abnormal touch sensation tingling, numbness, or unusual skin sensitivity reported in 12.520.9% of retatrutide patients at 12mg (varying by trial population), versus less than 1% with tirzepatide or semaglutide
Zepbound (Tirzepatide): Dual GLP-1 and GIP Activation Zepbound activates both GLP-1 receptors (like Wegovy) and adds GIP receptors into the equation
45.3% of the 12 mg administration group lost more than 30% of their weight, and 27.2% lost more than 35%
The growth follows a significant May ruling in which the court allowed key expert testimony regarding gastroparesis and other gastrointestinal injuries to proceed, preserving important evidence for plaintiffs as the litigation moves forward
.webp)
